Belvedere Trading
ONCT

Belvedere Trading’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Belvedere Trading’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,054
Closed -$170K – 632
2021
Q2 		$171K Sell
2,054
-2,339
-53% -$278K 0.01% 210
2021
Q1 		$731K Buy
+4,393
New +$581K 0.06% 68

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Belvedere Trading's ONCT Position: Q3 2021 in Review

Belvedere Trading sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2021, closing a stake of 2,054 shares — an estimated $170K sold.

Belvedere Trading first reported a position in ONCT in Q1 2021 and held it in 2 quarters. The position peaked at $731K in Q1 2021. 76 funds tracked by Wall St. Rank hold ONCT as of Q3 2021.

  • Belvedere Trading reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Belvedere Trading sold 2,054 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $170K.
  • Belvedere Trading first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Belvedere Trading's Oncternal Therapeutics, Inc. Common Stock position peaked at $731K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Belvedere Trading's 13F filing for Q3 2021, filed 19 Oct 2021.